Diabetes and obesity

Tirzepatide reduced BMI in adolescents with obesity in a 72-week trial

At 72 weeks, adolescents taking tirzepatide had an 18.5% mean BMI reduction, compared with a 0.5% increase with placebo.

Reported by 2 outlets Monday, November 16, 2026

Children eating lunch in a classroom
Photo: Public domain, U.S. Department of Agriculture

Once-weekly tirzepatide reduced BMI more than placebo in the phase III SURMOUNT-ADOLESCENTS trial, according to results presented at ObesityWeek and published in JAMA. The trial enrolled 160 adolescents with obesity or overweight and at least one weight-related complication. Participants received tirzepatide or placebo for 72 weeks alongside a healthy lifestyle intervention.

At week 72, mean BMI fell 18.5% with tirzepatide and increased 0.5% with placebo. A BMI reduction of at least 20% occurred in 48.1% of participants taking tirzepatide and 7.9% taking placebo. BMI fell below the 95th percentile for age and sex in 53.5% and 7.1%, respectively.

Gastrointestinal events were the most common adverse events, occurring in 81.5% of the tirzepatide group and 54.9% of the placebo group. Most were mild to moderate. An accompanying editorial urged clinicians to individualize dose increases based on patients’ responses and adverse effects.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.